Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia.
CHRM4
PACSIN3
gene polymorphism
schizophrenia
suicide
tardive dyskinesia
Journal
The application of clinical genetics
ISSN: 1178-704X
Titre abrégé: Appl Clin Genet
Pays: New Zealand
ID NLM: 101579789
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
01
2020
accepted:
02
04
2020
entrez:
6
5
2020
pubmed:
6
5
2020
medline:
6
5
2020
Statut:
epublish
Résumé
Previous studies have linked muscarinic M4 receptors (CHRM4) to schizophrenia. Specifically, the rs2067482 polymorphism was found to be highly associated with this disease. To test whether rs2067482 and rs72910092 are potential risk factors for schizophrenia and/or pharmacogenetic markers for antipsychotic-induced tardive dyskinesia. We genotyped DNA of 449 patients with schizophrenia and 134 healthy controls for rs2067482 and rs72910092 polymorphisms of the The frequency of genotypes and alleles of rs72910092 did not differ between patients with schizophrenia and control subjects. We did not reveal any statistical differences for both rs2067482 and rs72910092 between schizophrenia patients with and without tardive dyskinesia. The frequency of the C allele of the polymorphic variant rs2067482 was significantly higher in healthy persons compared to patients with schizophrenia (OR=0.51, 95% CI [0.33-0.80]; p=0.003). Accordingly, the CC genotype was found significantly more often in healthy persons compared to patients with schizophrenia (OR=0.49, 95% CI [0.31-0.80]; p=0.010). Our study found the presence of the minor allele (T) of rs2067482 variant being associated with schizophrenia. We argue that the association of rs2067482 with schizophrenia may be via its regulatory effect on some other gene with protein kinase C and casein Kknase substrate in neurons 3 (
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies have linked muscarinic M4 receptors (CHRM4) to schizophrenia. Specifically, the rs2067482 polymorphism was found to be highly associated with this disease.
PURPOSE
OBJECTIVE
To test whether rs2067482 and rs72910092 are potential risk factors for schizophrenia and/or pharmacogenetic markers for antipsychotic-induced tardive dyskinesia.
PATIENTS AND METHODS
METHODS
We genotyped DNA of 449 patients with schizophrenia and 134 healthy controls for rs2067482 and rs72910092 polymorphisms of the
RESULTS
RESULTS
The frequency of genotypes and alleles of rs72910092 did not differ between patients with schizophrenia and control subjects. We did not reveal any statistical differences for both rs2067482 and rs72910092 between schizophrenia patients with and without tardive dyskinesia. The frequency of the C allele of the polymorphic variant rs2067482 was significantly higher in healthy persons compared to patients with schizophrenia (OR=0.51, 95% CI [0.33-0.80]; p=0.003). Accordingly, the CC genotype was found significantly more often in healthy persons compared to patients with schizophrenia (OR=0.49, 95% CI [0.31-0.80]; p=0.010).
CONCLUSION
CONCLUSIONS
Our study found the presence of the minor allele (T) of rs2067482 variant being associated with schizophrenia. We argue that the association of rs2067482 with schizophrenia may be via its regulatory effect on some other gene with protein kinase C and casein Kknase substrate in neurons 3 (
Identifiants
pubmed: 32368127
doi: 10.2147/TACG.S247174
pii: 247174
pmc: PMC7183770
doi:
Types de publication
Journal Article
Langues
eng
Pagination
97-105Informations de copyright
© 2020 Pozhidaev et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
PLoS One. 2009 Dec 03;4(12):e8150
pubmed: 19997509
Front Neurosci. 2016 Nov 22;10:539
pubmed: 27920666
Am J Psychiatry. 2003 Jan;160(1):13-23
pubmed: 12505794
Int J Neuropsychopharmacol. 2000 Dec;3(4):285-296
pubmed: 11343606
Arch Gen Psychiatry. 2003 Jan;60(1):82-91
pubmed: 12511175
J Cell Sci. 2000 Dec;113 Pt 24:4511-21
pubmed: 11082044
Proc Jpn Acad Ser B Phys Biol Sci. 2013;89(6):226-56
pubmed: 23759942
Schizophr Bull. 1990;16(4):635-52
pubmed: 2077641
EMBO J. 2011 Sep 16;30(24):4955-69
pubmed: 21926968
Brain Dev. 2020 Jan;42(1):77-82
pubmed: 31477274
Handb Exp Pharmacol. 2012;(208):49-59
pubmed: 22222694
J Clin Psychopharmacol. 2007 Oct;27(5):423-30
pubmed: 17873670
Biol Psychiatry. 2016 Oct 1;80(7):509-21
pubmed: 27450032
World J Biol Psychiatry. 2017 Oct;18(7):492-505
pubmed: 28112043
World J Biol Psychiatry. 2020 Jan;21(1):72-77
pubmed: 30623717
Handb Exp Pharmacol. 2012;(208):223-41
pubmed: 22222701
Eur Neuropsychopharmacol. 2014 May;24(5):645-92
pubmed: 24820238
Biol Psychiatry. 2010 Feb 1;67(3):255-62
pubmed: 19897178
Biol Psychiatry. 2000 Sep 1;48(5):381-8
pubmed: 10978721
Nat Rev Drug Discov. 2013 Jan;12(1):25-34
pubmed: 23237917
Biomed J. 2013 May-Jun;36(3):118-24
pubmed: 23806881
Arch Gen Psychiatry. 1982 Apr;39(4):486-7
pubmed: 6121550
Brain Res. 2001 Mar 9;894(1):12-20
pubmed: 11245810
Gene. 2001 Jan 10;262(1-2):199-205
pubmed: 11179684
CNS Spectr. 2013 Feb;18(1):15-20
pubmed: 23593652
Eur J Pharmacol. 2015 Apr 15;753:114-26
pubmed: 25107282
Front Neural Circuits. 2017 May 22;11:35
pubmed: 28588455
Biol Psychiatry. 2007 May 15;61(10):1161-70
pubmed: 17239354
Eur J Pharmacol. 1999 Jul 2;376(1-2):119-25
pubmed: 10440097
Neuropharmacology. 2018 Jul 1;136(Pt C):362-373
pubmed: 29138080
Trends Neurosci. 1989 Apr;12(4):148-51
pubmed: 2470172
Mol Psychiatry. 2012 Sep;17(9):906-17
pubmed: 21747397
Schizophr Res. 2013 May;146(1-3):279-84
pubmed: 23490763
Life Sci. 2001 Apr 27;68(22-23):2605-13
pubmed: 11392633
Schizophr Bull. 2009 May;35(3):549-62
pubmed: 19325164
Int J Neuropsychopharmacol. 2001 Dec;4(4):347-60
pubmed: 11806860
Clin Genet. 2015 Apr;87(4):356-61
pubmed: 24697219